About: The Effectiveness of Convalescent Plasma and Hyperimmune Immunoglobulin for the Treatment of Severe Acute Respiratory Infections of Viral Etiology: A Systematic Review and Exploratory Meta-analysis

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: The Effectiveness of Convalescent Plasma and Hyperimmune Immunoglobulin for the Treatment of Severe Acute Respiratory Infections of Viral Etiology: A Systematic Review and Exploratory Meta-analysis Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	The Effectiveness of Convalescent Plasma and Hyperimmune Immunoglobulin for the Treatment of Severe Acute Respiratory Infections of Viral Etiology: A Systematic Review and Exploratory Meta-analysis
Creator	Nguyen-Van-Tam, Jonathan Mair-Jenkins, John Cleary, Paul Khaw, Fu-Meng Makki, Sophia Saavedra-Campos, Maria Rooney, Kevin Beck, Charles Group, Study Kenneth Baillie, J Lim, Wei Plasma, Convalescent
source	Medline; PMC
abstract	Background. Administration of convalescent plasma, serum, or hyperimmune immunoglobulin may be of clinical benefit for treatment of severe acute respiratory infections (SARIs) of viral etiology. We conducted a systematic review and exploratory meta-analysis to assess the overall evidence. Methods. Healthcare databases and sources of grey literature were searched in July 2013. All records were screened against the protocol eligibility criteria, using a 3-stage process. Data extraction and risk of bias assessments were undertaken. Results. We identified 32 studies of SARS coronavirus infection and severe influenza. Narrative analyses revealed consistent evidence for a reduction in mortality, especially when convalescent plasma is administered early after symptom onset. Exploratory post hoc meta-analysis showed a statistically significant reduction in the pooled odds of mortality following treatment, compared with placebo or no therapy (odds ratio, 0.25; 95% confidence interval, .14–.45; I(2) = 0%). Studies were commonly of low or very low quality, lacked control groups, and at moderate or high risk of bias. Sources of clinical and methodological heterogeneity were identified. Conclusions. Convalescent plasma may reduce mortality and appears safe. This therapy should be studied within the context of a well-designed clinical trial or other formal evaluation, including for treatment of Middle East respiratory syndrome coronavirus CoV infection.
has issue date	2015-01-01(xsd:dateTime)
bibo:doi	10.1093/infdis/jiu396
bibo:pmid	25030060
has license	cc-by-nc-nd
sha1sum (hex)	f46ad7149ec602bd131fd370682f1b73235cfacc
schema:url	https://doi.org/10.1093/infdis/jiu396
resource representing a document's title	The Effectiveness of Convalescent Plasma and Hyperimmune Immunoglobulin for the Treatment of Severe Acute Respiratory Infections of Viral Etiology: A Systematic Review and Exploratory Meta-analysis
has PubMed Central identifier	PMC4264590
has PubMed identifier	25030060
schema:publication	J Infect Dis
resource representing a document's body	covid:f46ad7149ec602bd131fd370682f1b73235cfacc#body_text
is schema:about of	named entity 'EFFECTIVENESS' named entity 'IMMUNOGLOBULIN' named entity 'VIRAL' named entity 'Effectiveness' named entity 'CLINICAL BENEFIT' named entity 'ACUTE RESPIRATORY INFECTIONS' named entity 'SYSTEMATIC REVIEW' covid:arg/f46ad7149ec602bd131fd370682f1b73235cfacc named entity 'BACKGROUND' named entity 'ACUTE RESPIRATORY INFECTIONS' named entity 'ETIOLOGY' named entity 'TREATMENT' named entity 'SEVERE' named entity 'SEVERE' named entity 'MAY BE' named entity 'VIRAL' named entity 'META-ANALYSIS' named entity 'ETIOLOGY' named entity 'ADMINISTRATION' named entity 'OVERALL' named entity 'IMMUNOGLOBULIN' named entity 'META-ANALYSIS' named entity 'SYSTEMATIC REVIEW' named entity 'SERUM' named entity 'ASSESS' named entity 'TREATMENT' named entity 'EVIDENCE' named entity 'convalescent' named entity 'Viral' named entity 'Acute Respiratory Infections' named entity 'adverse event' named entity 'World Health Organization' named entity 'convalescent plasma' named entity 'selection bias' named entity 'etiology' named entity 'infection' named entity 'severe acute respiratory syndrome coronavirus' named entity 'influenza' named entity 'convalescent plasma' named entity 'infection' named entity 'infection' named entity 'Convalescent plasma' named entity 'randomized control trial' named entity 'MERS-CoV' named entity 'steroids' named entity 'SARS-CoV' named entity 'infection' named entity 'comorbidities' named entity 'titer' named entity 'A(H1N1)pdm09' named entity 'convalescent plasma' named entity 'confounding' named entity 'clinical trial' named entity 'convalescent plasma' named entity 'A(H1N1)pdm09' named entity 'Spanish influenza' named entity 'convalescent plasma' named entity 'convalescent plasma' named entity 'convalescent plasma' named entity 'subgroup analysis' named entity 'SARI' named entity '95% CI' named entity 'convalescent plasma' named entity 'immunoglobulin' named entity 'influenza' named entity 'critical care' named entity 'influenza' named entity '85%' named entity 'WHO' named entity 'Agency for Healthcare Research and Quality'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software